They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.
The study details the validation of the mass spec-based preterm birth test, which the company launched nationwide last month through its agreement with LabCorp.
The agreement will allow Sera to leverage LabCorp's sales force and networks, but similar deals have failed to deliver for proteomics firms in the past.
Sera plans to make the test for preterm birth available nationwide this year with LabCorp as the exclusive US distributor.
A health-economic model of the company's preterm birth test found it could lower infant mortality by 23 percent and yield annual savings of around $500 million.
According to one physician familiar with the test, it is a much needed diagnostic tool, but without insurance coverage it is too expensive for wide use.
Published this week in AJOG, the study found that the test could predict delivery before 37 weeks with 75 percent sensitivity and 74 percent specificity.
The mass spec-based proteomic test identified women who gave birth at or before 35 weeks gestation with an area under the receiver operating curve of .93.
This fall the company is rolling out a limited commercial launch of the MRM mass spectrometry-based proteomic test, with a broader launch to come next year.
With the additional funding, Sera aims to develop new tests for predicting the risk of preterm birth in women in developing countries, the company said.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.